The uniqueness of this case lies in the specific combination of HER2-positive breast cancer, the development of PDAC, the absence of canonical hereditary mutations, and the finding of multiple VUS in conjunction with somatic TP53 mutations in both tumors. This evidence concerns the gene ERBB2 and breast carcinoma.